IonQ Unveils New Enterprise-Grade Quantum OS and Hybrid Services Suite
Full stack development approach drives enterprise-grade capabilities, enabling improved quantum functionality for commercial applicationsIonQ Quantum OS drives an average reduction of over 50 percent in on-system classical overhead, improving time to solution for quantum workloads
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the launch of its quantum operating system, now called IonQ Quantum OS, and a collection of new capabilities named IonQ Hybrid Services suite. These technologies will greatly advance performance and utility of quantum computing for enterprise customers.
IonQ Quantum OS is a nearly ground-up rewrite of IonQ’s original quantum operating system. Designed and built with a flexible and modular architecture, it is designed to scale and adapt with IonQ’s hybrid quantum computing ecosystem and power IonQ’s current and future flagship quantum computers, including IonQ Forte and IonQ Forte Enterprise.
Designed for improved performance, IonQ Quantum OS dramatically improves time-to-solution, including:
- An average reduction of over 50 percent in on-system classical overhead (compared to identical workloads run on IonQ Forte before the improvements were deployed).
- An 85 percent reduction in cloud and network overhead of workloads submitted through the IonQ Cloud.
- Up to 100x improved accuracy in an expanded error mitigation and compilation suite.
- Enhanced calibration, automation, and control software and firmware to optimize qubit and gate performance and adjust for systemic drifts, resulting in better algorithmic performance.
IonQ Quantum OS also offers enterprise-grade security through improved observability and enhanced interoperability across on-premise hardware and software solutions. These improvements provide customers with new options for securely integrating quantum computing into their stack. IonQ Quantum OS has been running commercial workloads on IonQ Forte since summer 2024 and will soon be operational in controlling IonQ Forte Enterprise as it comes online in IonQ’s Basel, Switzerland data center.
“We designed our Quantum OS not only to address the complex demands of today’s enterprises but to scale seamlessly as their needs evolve,” said Peter Chapman, President and CEO of IonQ. “Our goal is to empower enterprise customers to unlock new possibilities and drive innovation with quantum computing.”
Showcased as an early preview with NVIDIA at SuperCompute 2024, IonQ’s new Hybrid Services suite is designed to enable seamless development and deployment of hybrid workloads that integrate IonQ quantum computers with high-performance classical resources over the cloud. This suite introduces significant advancements to enhance the speed, performance, and usability of quantum workloads, including:
- The Workload Management & Solver Service, a quantum developer toolkit that offers capabilities to efficiently move hybrid workloads to the cloud. This service features a quantum function and hybrid solver designed to help developers simplify the process of manually building circuits and iterative algorithms by packaging them into portable workloads to be executed and enhanced based on their needs.
- A new scheduling feature, Sessions, built on top of IonQ’s Fair Share scheduling engine, is designed to streamline provisioning of QPU time so that iterative and resource-intensive workflows run with minimal wait and interruption. Sessions also provides expanded support for offerings from IonQ’s cloud partners, including Amazon Braket Hybrid Jobs and Azure Quantum Sessions.
- The all-new IonQ SDK allows for seamless, simple, and reliable integration with IonQ Quantum Cloud API and IonQ Hybrid Services.
IonQ Hybrid Services suite is already accelerating the development of real-world, commercial quantum hybrid applications with customers. IonQ recently worked with Oak Ridge National Laboratory (ORNL) to implement a beta version of Hybrid Services to support the development of a NISQ-friendly quantum algorithm, which accelerates time-to-solution for hard optimization problems.
To learn more about IonQ and its latest system news and business developments, visit https://ionq.com.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words ”will,” “expect,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the expected benefits of IonQ’s quantum operating system and hybrid services suite, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, IonQ’s quantum computing capabilities and plans, the commercial relevance and advantages of applications, and the performance, scalability, accessibility, ease of use, capacity, power, speed, latency, quality, and reliability of IonQ’s quantum computing offerings. IonQ’s quantum computing capabilities and plans, improved efficiency and speed of quantum workloads and algorithms run on IonQ’s quantum computers, and the scalability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; and events that may impact the security, quality and reliability of IonQ’s technology. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202941767/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom